secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-07-29T20:07:19+00:00
Accession:  0001628280-26-050607
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q2 revenue up 32% to $256M; raises FY2026 guidance to $1.1-1.2B
-----------------------------------------------------------------------

- Revenue $256.1M (+32% YoY); net income $43.0M ($0.36 diluted EPS) vs $35.1M ($0.29) in Q2 2025.
- Lifyorli (relacorilant) generated $47.6M in first quarter of availability; over 1,300 patients started treatment.
- FY2026 revenue guidance increased to $1.1-1.2 billion.
- NDA for relacorilant in Cushing's syndrome resubmitted; PDUFA date December 17, 2026.
- Cash and investments $544.6M at June 30, 2026, up from $515.4M at March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/0001628280-26-050607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026050607/cort-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-050607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer